Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 15, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
The professor of neurology at NYU Langone Grossman School of Medicine broke down the knowns and unknowns about long-term changes related to COVID-19, their legitimacy, and their associations with neurodegenerative disorders.
In Episode 6 of the NeurologyLive® Peers & Perspectives series, "Improving Diagnosis and Patient Outcomes in Narcolepsy," Russell Rosenberg, PhD, DABSM, and Margaret Park, MD, explore the use of nonpharmacologic treatment approaches for the management of narcolepsy.
Following their data presentation on AMX0035 at AAN 2022 and the FDA Advisory Committee vote on the phase 2/3 trial data, Justin Klee and Josh Cohen, the cofounders and cochief operating officers of Amylyx Pharmaceuticals, shared their perspectives on the agent.
The medical director and chief medical officer of the New England Center for Neurology and Headache discussed notable data from the STEMTRA trial, and the progress made in the field of regenerative medicine.
New neurological deficits were a predictor of long-term survival regardless of the status epilepticus cause and were associated with a 5-fold increase in the odds of death 2 years after status epilepticus diagnosis.